Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06124300 · ClinicalTrials.gov registry record · NA

Effects of a Female Hormone Balance Supplement on Symptoms of Polycystic Ovary Syndrome and Severe Premenstrual Syndrome

A NA study of Polycystic Ovary Syndrome and Premenstrual Syndrome, sponsored by Rael.

Completed
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT06124300: Completed NA study of Polycystic Ovary Syndrome and Premenstrual Syndrome, sponsored by Rael.

NCT06124300 is a NA study of Polycystic Ovary Syndrome and Premenstrual Syndrome that has completed, run by Rael. The registered enrollment target is 40 participants, below the 17,257-participant average among 30 other Polycystic Ovary Syndrome trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06124300, a NA study of Polycystic Ovary Syndrome and Premenstrual Syndrome, has completed, sponsored by Rael.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This is a virtual single group study that will last 12 weeks. Participants will take 1 scoop of the female hormone balance supplement, and mix it with their drink of choice every morning. Questionnaires will be completed at baseline, 1 week, 2 weeks, 4 weeks, and 12 weeks

Primary Outcome

Study-specific questionnaires completed by participants. Questionnaires utilize a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Very regular") and 1 representing the least favorable/worst outcome (e.g., "Extremely irregular").

Interventions

  • DIETARY_SUPPLEMENT Female Hormone Balance Supplement

Study Locations (1)

California

  • Citruslabs - Santa Monica

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-08-30
Est. Completion 2024-01-19
Phase NA
Rael

5 total trials

What the finished NCT06124300 record still lists

NCT06124300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 17,257-participant average among 30 other Polycystic Ovary Syndrome trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Polycystic Ovary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Female Hormone Balance Supplement is the first listed.

NCT06124300 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06124300 about?

NCT06124300 is a clinical study titled "Effects of a Female Hormone Balance Supplement on Symptoms of Polycystic Ovary Syndrome and Severe Premenstrual Syndrome". This is a virtual single group study that will last 12 weeks. Participants will take 1 scoop of the female hormone balance supplement, and mix it with their drink of choice every morning. Questionnaires will be completed at baseline, 1 week, 2 weeks, 4 weeks, and 12 weeks

What is the current status of trial NCT06124300?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2023-08-30. Estimated completion is 2024-01-19.

What conditions does trial NCT06124300 study?

This clinical trial studies the following conditions: Polycystic Ovary Syndrome, Premenstrual Syndrome.

What interventions are being tested in trial NCT06124300?

The interventions under investigation include: Female Hormone Balance Supplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06124300?

This trial is sponsored by Rael, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06124300 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Polycystic Ovary Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06124300's enrollment target sits among peer trials

40 20th of 30 higher than 10 of 30 other Polycystic Ovary Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Polycystic Ovary Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06124300, the US trial registry maintained by the National Library of Medicine. NCT06124300 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.